Grants Directory

The International Clinical Trial Collaborations Grant Opportunity will provide support for Australian research teams to conduct clinical trial research in collaboration with international counterparts. Applications to this grant opportunity must propose a single clinical trial that will promote Australian involvement in international collaborative investigator-initiated clinical trials research through the establishment and co‑ordination of clinical trial site/s in Australia, and provide high-quality evidence of the effectiveness of novel health treatments, drugs or devices in ‘usual care’ settings, which will support a decision on whether to deliver the intervention in an Australian setting. Novel health treatments include new and innovative applications of existing interventions.

Provides up to $1 million in matching funding to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage.

Applicants must have an ABN and be incorporated in Australia. In accordance with s24 of the Medical Research Future Fund Act 2015, applicants must be one of the following eligible bodies: a medical research institute, a university, a corporate Commonwealth entity, a corporation (including businesses and not for profits). Further criteria are listed on the website.

The objectives of this grant opportunity are to fund large scale pilot research studies into pathogen genomics late in the research and development pipeline aiming to demonstrate clinical and/or public health utility, cost-effectiveness, and capacity for translation of genomics in the clinic, in recognition that such evidence is critical to the adoption of genomics in mainstream healthcare. The minimum grant amount is $1 million. The maximum grant amount is $10 million. The grant amount will be up to 100 per cent of eligible project costs.

Applicants must have an ABN and be incorporated in Australia. In accordance with s24 of the Medical Research Future Fund Act 2015, applicants must be one of the following eligible bodies: a medical research institute, a university, a corporate Commonwealth entity, a corporation (including businesses and not for profits).

The Congenital Heart Disease (CHD) grant opportunity forms part of the Accelerated Research initiative, funded through the Medical Research Future Fund (MRFF). The CHD grant opportunity supports research to provide new diagnoses and treatment options for those suffering from congenital heart disease. For this grant opportunity $20 million is available over 5 years from 2019-20 to 2023-24. There is no minimum grant amount. The maximum grant amount is $10 million. The grant amount will be up to 100 per cent of eligible project costs. You must complete your project by 30 June 2024.

Applicants must have an ABN and be incorporated in Australia. In accordance with s24 of the Medical Research Future Fund Act 2015, applicants must be one of the following eligible bodies: a medical research institute, a university, a corporate Commonwealth entity, a corporation (including businesses and not for profits).

The Researcher Exchange and Development within Industry Initiative has been reopened to allow tax exempt entities to apply. REDI is supported by the Medical Research Future Fund. The objective of the fund is to strategically fund research and address national priorities in a cohesive and coordinated way. We will fund one service provider who will be responsible for facilitating connections between industry, universities, registered training organisations and government entities, and delivering, potentially in collaboration with joint-service partners’ relevant training programs, industry placements, mentoring and exchange programs for researchers.

Applicants must have an ABN and be incorporated in Australia. In accordance with s24 of the Medical Research Future Fund Act 2015, applicants must be one of the following eligible bodies: a medical research institute, a university, a corporate Commonwealth entity, a corporation (including businesses and not for profits).

The International Clinical Trial Collaborations Grant Opportunity will provide support for Australian research teams to conduct clinical trial research in collaboration with international counterparts. Applications to this grant opportunity must propose a single clinical trial that will promote Australian involvement in international collaborative investigator-initiated clinical trials research through the establishment and co‑ordination of clinical trial site/s in Australia, and provide high-quality evidence of the effectiveness of novel health treatments, drugs or devices in ‘usual care’ settings, which will support a decision on whether to deliver the intervention in an Australian setting. Novel health treatments include new and innovative applications of existing interventions.

To conduct transformative translational research that will accelerate the translation of research findings into scalable solutions to health service problems, directly benefitting patients and closing the loop between health care practice and research.

Contact: Assoc Prof Angela Todd
Phone: 0468 761 451
Email: sydneyhealthpartners.snrprojectofficer@sydney.edu.au

The purpose of the research grant scheme is to undertake and source relevant, high quality research that informs NSW Agency for Clinical Innovation mandate, functions, strategic plan and priorities. The ACI provides funding for selected research grants, allocating grant funds across several small to medium size projects. These projects should reflect the ACI research priorities, and be 1.5 years in duration.

Contact: Ivana Goluza Riddell
Phone: 0409 289 642
Email: ACI-Research@health.nsw.gov.au